GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation : A Case Report. / Iepsen, Eva W.; Have, Christian T; Veedfald, Simon; Madsbad, Sten; Holst, Jens J; Grarup, Niels; Pedersen, Oluf; Brandslund, Ivan; Holm, Jens-Christian; Hansen, Torben; Torekov, Signe S.

In: Cell Reports Medicine, Vol. 1, No. 1, 100006, 2020.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Iepsen, EW, Have, CT, Veedfald, S, Madsbad, S, Holst, JJ, Grarup, N, Pedersen, O, Brandslund, I, Holm, J-C, Hansen, T & Torekov, SS 2020, 'GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report', Cell Reports Medicine, vol. 1, no. 1, 100006. https://doi.org/10.1016/j.xcrm.2020.100006

APA

Iepsen, E. W., Have, C. T., Veedfald, S., Madsbad, S., Holst, J. J., Grarup, N., Pedersen, O., Brandslund, I., Holm, J-C., Hansen, T., & Torekov, S. S. (2020). GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report. Cell Reports Medicine, 1(1), [100006]. https://doi.org/10.1016/j.xcrm.2020.100006

Vancouver

Iepsen EW, Have CT, Veedfald S, Madsbad S, Holst JJ, Grarup N et al. GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report. Cell Reports Medicine. 2020;1(1). 100006. https://doi.org/10.1016/j.xcrm.2020.100006

Author

Iepsen, Eva W. ; Have, Christian T ; Veedfald, Simon ; Madsbad, Sten ; Holst, Jens J ; Grarup, Niels ; Pedersen, Oluf ; Brandslund, Ivan ; Holm, Jens-Christian ; Hansen, Torben ; Torekov, Signe S. / GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation : A Case Report. In: Cell Reports Medicine. 2020 ; Vol. 1, No. 1.

Bibtex

@article{5e597b07319f41a09ceec970cd7920b4,
title = "GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report",
abstract = "Individuals with obesity due to pathogenic heterozygous melanocortin 4 receptor (MC4R) mutations can be treated efficiently with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide. Here, we report the effect of 16 weeks of liraglutide 3 mg/day treatment in a woman with morbid obesity and type 2 diabetes (T2D) due to homozygous pathogenic MC4R mutation. The body weight loss was 9.7 kg, similar to weight loss in heterozygous MC4R mutation carriers and common obesity. In addition, the treatment led to clinically relevant decreases in fasting glucose, triglycerides, systolic blood pressure, and normalization of glucose tolerance. We conclude that liraglutide reduces body weight and blood glucose levels in hetero- and homozygous MC4R mutation carriers. This serves as proof-of-concept that MC4Rs are not required for the body weight and glucose lowering effects of GLP-1 RAs and that liraglutide may be used as part of the treatment of obesity and T2D due to MC4R mutations.",
author = "Iepsen, {Eva W.} and Have, {Christian T} and Simon Veedfald and Sten Madsbad and Holst, {Jens J} and Niels Grarup and Oluf Pedersen and Ivan Brandslund and Jens-Christian Holm and Torben Hansen and Torekov, {Signe S}",
year = "2020",
doi = "10.1016/j.xcrm.2020.100006",
language = "English",
volume = "1",
journal = "Cell Reports Medicine",
issn = "2666-3791",
publisher = "Cell Press",
number = "1",

}

RIS

TY - JOUR

T1 - GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation

T2 - A Case Report

AU - Iepsen, Eva W.

AU - Have, Christian T

AU - Veedfald, Simon

AU - Madsbad, Sten

AU - Holst, Jens J

AU - Grarup, Niels

AU - Pedersen, Oluf

AU - Brandslund, Ivan

AU - Holm, Jens-Christian

AU - Hansen, Torben

AU - Torekov, Signe S

PY - 2020

Y1 - 2020

N2 - Individuals with obesity due to pathogenic heterozygous melanocortin 4 receptor (MC4R) mutations can be treated efficiently with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide. Here, we report the effect of 16 weeks of liraglutide 3 mg/day treatment in a woman with morbid obesity and type 2 diabetes (T2D) due to homozygous pathogenic MC4R mutation. The body weight loss was 9.7 kg, similar to weight loss in heterozygous MC4R mutation carriers and common obesity. In addition, the treatment led to clinically relevant decreases in fasting glucose, triglycerides, systolic blood pressure, and normalization of glucose tolerance. We conclude that liraglutide reduces body weight and blood glucose levels in hetero- and homozygous MC4R mutation carriers. This serves as proof-of-concept that MC4Rs are not required for the body weight and glucose lowering effects of GLP-1 RAs and that liraglutide may be used as part of the treatment of obesity and T2D due to MC4R mutations.

AB - Individuals with obesity due to pathogenic heterozygous melanocortin 4 receptor (MC4R) mutations can be treated efficiently with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide. Here, we report the effect of 16 weeks of liraglutide 3 mg/day treatment in a woman with morbid obesity and type 2 diabetes (T2D) due to homozygous pathogenic MC4R mutation. The body weight loss was 9.7 kg, similar to weight loss in heterozygous MC4R mutation carriers and common obesity. In addition, the treatment led to clinically relevant decreases in fasting glucose, triglycerides, systolic blood pressure, and normalization of glucose tolerance. We conclude that liraglutide reduces body weight and blood glucose levels in hetero- and homozygous MC4R mutation carriers. This serves as proof-of-concept that MC4Rs are not required for the body weight and glucose lowering effects of GLP-1 RAs and that liraglutide may be used as part of the treatment of obesity and T2D due to MC4R mutations.

U2 - 10.1016/j.xcrm.2020.100006

DO - 10.1016/j.xcrm.2020.100006

M3 - Journal article

C2 - 33205056

VL - 1

JO - Cell Reports Medicine

JF - Cell Reports Medicine

SN - 2666-3791

IS - 1

M1 - 100006

ER -

ID: 258280146